The DIABLO Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma epithelial cell line, with disruption of the DIABLO gene (SMAC). This heterogeneous pool enables loss-of-function studies of apoptotic signaling without clonal artifacts.
The AGS cell line, originating from a gastric adenocarcinoma, is a widely used model for gastric cancer research, retaining epithelial characteristics and relevant signaling pathways. It is employed in assays of viability, chemosensitivity, and apoptosis, making it an appropriate host for investigating tumor cell survival mechanisms.
DIABLO is a pro-apoptotic mitochondrial protein released into the cytosol in response to apoptotic stimuli such as DNA damage, p53, TNF-alpha, TRAIL, or FAS ligand. Upon release, it binds and inhibits IAPs??including XIAP, cIAP1, cIAP2, and survivin??thereby derepressing initiator caspase-9 and effector caspases-3 and -7. This action is central to both intrinsic and extrinsic apoptotic cascades. In the intrinsic pathway, cytochrome c and Apaf-1 form the apoptosome, activating caspase-9, which is potentiated by DIABLO-mediated neutralization of XIAP. Upstream, BAX and BAK mediate mitochondrial outer membrane permeabilization, while Bcl-2 opposes this step. DIABLO also cooperates with HTRA2 in IAP antagonism.
In gastric cancer, apoptosis resistance underlies tumor progression and chemoresistance. AGS cells exhibit such defects, and DIABLO disruption allows dissection of mitochondrial apoptotic contributions to drug sensitivity, particularly to agents like cisplatin. This model is instrumental for exploring IAP overexpression and for assessing IAP inhibitor strategies to restore apoptotic competence in gastric epithelial malignancies.
Applications encompass apoptosis regulation studies, chemoresistance investigation, and IAP inhibitor screening. Key assays include western blotting for DIABLO, XIAP, and caspases; cell viability (MTT, ATP); apoptosis detection (Annexin V/PI, TUNEL); caspase activity assays; cytochrome c release; co-immunoprecipitation of DIABLO with XIAP; drug sensitivity tests (cisplatin, staurosporine); immunofluorescence for mitochondrial release; and RT-qPCR for DIABLO mRNA. These methods enable detailed analysis of mitochondrial integrity, death receptor signaling, and pathway crosstalk. For further details, contact Ascent Research.
